He Jiankui’s Genetic Misadventure, Part 2: How Different Are Chinese and Western Bioethics?
By Jing-Bao Nie, Neil Pickering,
Hastings Bioethics Forum
| 12. 13. 2018
When the world’s first research on editing the genes of human embryos by Chinese scientists was published in an international journal in 2015, a report in the New York Timescharacterised the key issue involved as “a scientific ethical divide between China and West.” Earlier this year, an article in the magazine Foreign Policy by a researcher with Chinese origin put it bluntly that “China will always be bad at bioethics.” Now, He Jiankui’s announcement on gene-edited babies appears to provide more compelling evidence that China is the “radical other” of the West, a wild land where bioethics matters little.
Is this really the right way to look at things? Our answer is, no. The evidence doesn’t bare these beliefs out; it is a misdiagnosis, and it risks obscuring the real issues that He Jiankui’s experimentation raises. Since the news on the gene-edited babies came out on November 26 via Baidu and Google, one of us (Nie) has been closely following reactions to it in journalists’ reports, commentaries, and posts on Chinese and international mass media, as well as on...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...